Skip to content
TrialMatch
Sign up
Recruiting

The Application of 18F-G1 PET/CT Targeting Granzyme B in the Pan-cancer Immunotherapy

Create a profile to match View the full record on ClinicalTrials.gov

About this study

The purpose of this study is to explore the effectiveness of 18F-G1 PET/CT in patients with solid tumors and hematological malignancies receiving immunotherapy

Condition
Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Lymphoma
Tested
18F-G1
Sponsor
Peking University First Hospital

Who can join

Age
18 to 75 years
Sex
All sexes
Healthy volunteers
Accepted

Inclusion 10

  • Minimum age: 18 years
  • Maximum age: 75 years
  • Study condition: Solid Tumor Malignancies, Hematologic Cancer, Lung Cancer, Esophagus Cancer, Breast Cancer, Kidney Cancer, Stomach Cancer, Lymphoma
  • Subjects diagnosed with a malignant tumor by histopathology who are going to receive immunotherapy (monotherapy or combined immunotherapy) recommended by the multidisciplinary team.
  • Subjects didn't receive previous immunotherapy.
  • There exists at least one measurable target lesion according to the RECIST 1.1.
  • ECOG performance status≤2.
  • The expected survival time is ≥6 months.
  • Effective contraceptive measures will be adopted during the study period and within 6 months after the study.
  • Willing and able to fully understand and sign the informed consent form.

Exclusion 6

  • Women in the preconception period, pregnancy, or lactation period.
  • Combined with other malignant tumor.
  • Diagnosed with autoimmune disease, or have long history of systemic steroid hormone therapy or immunosuppressive therapy.
  • Having a history of severe cardiovascular disease, severe hepatic and renal insufficiency.
  • Receiving radiotherapy or interventional therapy during the immunotherapy.
  • 18F-G1 PET/CT or 18F-FDG PET/CT is not performed in our department, or the interval between baseline imaging and immunotherapy is more than 30 days.

Where

1 site, 1 recruiting

Peking University First Hospital

Beijing, China

Recruiting

Contact

Potential match only. Final eligibility is determined by the study team.